It may fairly be claimed that up to the last decade no antiepileptic drug (AED) had undergone rigorous testing. The development programmes of the new AEDs registered in recent years have necessarily been innovative, and methods of AED testing are still undergoing rapid evolutionary change. Clinical evaluation of AEDs is both difficult and complex, due mainly to two factors: (1) intermittence of clinical events, which means that dosing for periods of several weeks is generally necessary, leading to problems of poor compliance and inaccurate reporting of events by carers and patients; and (2) therapeutic necessity, which means that it is, in general, unacceptable to withhold effective treatment from a person with epilepsy. Consequently monotherapy, either with a trial drug or with placebo, can rarely be justified. In consequence most phase II trials use add-on therapy which in turn causes various problems. Conventional phase II AED trials are usually placebo-controlled addon studies employing either a parallel or crossover design. The latter is subject to a number of practical and theoretical objections, notably on grounds of carry-over and order effects. Increasing attention has recently been directed to ethically acceptable monotherapy designs. One approach first exploited in the development of felbamate is the performance of monotherapy trials in patients whose AEDs have been withdrawn as part of a preoperative assessment protocol. Other possibilities for achieving monotherapy are also discussed.
INTRODUCTION
It may fairly be claimed that up to the last decade no antiepileptic drug (AED) had undergone rigorous testing. Coatsworth 1 in a comprehensive review of AED assessment, reported three controlled trials up to that date, and by 1976 Richens was able to identify some 172. Gram et al 3 found 51 by 1982, but the majority suffered gross methodological deficiences. In the same year, on being asked to give a talk on the efficacy of the most recently registered AED, clonazepam, I was embarrassed to discover that of 210 efficacy studies, only six were controlled, and those so gravely flawed as to be uninterpretable 4. In the past decade the situation has changed dramatically, the number of controlled AED trials currently in progress must exceed the total of those completed before 1983. The development programmes of the new AEDs registered in recent years have necessarily been innovative, and methods of AED testing are still undergoing rapid evolutionary change.
WHY AEDS ARE HARD TO TEST
Clinical evaluation of AEDs is both difficult and complex, due mainly to two factors: intermittence of clinical events and therapeutic necessity.
Intermittence of clinical events
The clinical manifestations of epilepsy are intermittent, and prolonged study is therefore necessary to demonstrate efficacy. Except in the case of those types of seizures that occur many times daily (as absences), this generally demands that dosing continues for periods of several weeks. This requirement leads to other problems.
1. Prolonged toxicological studies must be completed prior to phase II investigations. 2. Unless the subjects are so disabled as to require hospitalization on clinical grounds (not an ideal group for demonstrating efficacy), studies will be performed in outpatients without close supervision. This in turn creates or exacerbates other difficulties (3-5 below 
Therapeutic necessity
It is, in general, unacceptable to withhold effective treatment from a person with epilepsy. Monotherapy either with a trial drug or with placebo can therefore be justified only under special circumstances (see below). In consequence, most phase II trials use add-on therapy which in turn causes various other problems.
1. Drug interactions may confound both therapeutic and adverse effects. Elevation of blood levels of co-medication may cause intoxication, which may be wrongly attributed to the experimental agent, may break the blinding, or indeed lead to abandonment of the trial. The difficulties are well illustrated by recent trials of the imidazoles, nafimidone and denzimol 5,s. Converseley, efficacy may be wrongly ascribed to a new product because it causes an increase in concentrations of co-medication; thus sulthiame probably owed most of its apparent antiepileptic action to elevation of phenytoin levels 7. Conversely, induction of metabolism of the co-medication could produce lower than expected blood levels and result in a failure to demonstrate any beneficial effect of the experimental drug.
Difficulties in blinded dosing of the experimental drug itself will arise if its metabolism is influenced by the co-medication, as is well illustrated in the case of lamotrigine which has a reduced half-life in patients taking enzyme inducers, such as carbamazepine, and a greatly delayed metabolism in those on valproate monotherapy s.
Such problems are not insuperable, but require some special precautions to be taken in trial design. For instance, in an add-on study of felbamate, Leppik et al 9, knowing the trial drug reduced clearance of phenytoin and increased that of carbamazepine, . . . used an unblinded monitor to adjust dosage so as to keep concentrations of the comedication at baseline values. Conversely, Binnie et all° compensated for the effects of co-medication on lamotrigine metabolism, again by the use of an unblinded investigator who calculated lamotrigine half-lives from observations in the first week of dosing and individualized each patient's regime thereafter. Pharmacokinetic interactions apart, any demonstrated efficacy or adverse effects may depend on a pharmacodynamic synergy with the co-medication. The population studied is necessarily drug resistant and a product of great potential value (due, for instance, to exceptional tolerability or favourable pharmacokinetics) may show no effect and be rejected. Registration is likely to be granted only for the indication tested, which may address only that 20% of the potential AED market represented by people resistant to existing drugs.
CONVENTIONAL TRIAL DESIGNS
Conventional phase II AED trials are usually placebo-controlled, add-on studies employing either a single period parallel group ('parallel') or multiple periods within patients ('crossover') design. Theoretical considerations favour the parallel design as the crossover has many disadvantages.
1. In practice, crossover trials typically involve two 3-month treatment periods ( stance. A baseline period is required to establish stability of dosing with comedication, seizure documentation, etc. possibly a further 8 weeks. A washout period is required between phases I and II for withdrawal of the drug from those patients receiving it in phase I. The duration of this washout depends on the known pharmacokinetic and dynamic properties of the substance; it must be long enough to allow gradual dose reduction to minimize the risk of withdrawal seizures. If the drug is believed to have a prolonged action it is desirable that sufficient time should elapse for this to have ended before phase II. Four weeks would be a typical duration for this period. A further washout will be required for withdrawal after phase II. It will be seen that in a typical crossover AED trial each patient will be required to participate for some 40 weeks. Dropouts due to withdrawal of consent, non-compliance, or intercurrent life events may therefore present a major problem in crossover trials. 2. Even after precautions have been taken, by the use of apparently adequate baseline and washout periods, carry-over and order effects may occur. If the test drug has an action more prolonged than supposed, or indeed produces a lasting change in epilepsy, it may be found that seizure counts on placebo are greater in those subjects who do not receive active drug until phase II and less in those who take placebo in phase II, having had the verum in phase I. Admission criteria usually include a minimum seizure frequency. Patients with unstable epilepsy may meet the criteria and be recruited during a period in which their seizures are more than usually frequent. Over subsequent months there will therefore be a tendency for this selected group to show a regression towards their habitual mean seizure frequency, with a progressive reduction in seizures from baseline, through phase I and into phase II. Thus the active drug may appear more efficacious in phase II than in phase I.
Sound design, notably the use of adequate baseline and washout periods, may help to reduce both carryover and treatment/period effects. If they nevertheless occur, appropriate statistical methods are available, but these are generally regarded as a last resort to salvage an otherwise uninterpretable trial.
Ethical difficulties may arise if patients
show a clinically important reduction in seizures during phase I. It may then be considered unacceptable (indeed the patient . .
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may refuse) to change to the alternative, presumed placebo treatment for phase II. Attempts to avoid this dilemma by use of a single-blind design, giving placebo to all patients in phase I, is not a satisfactory solution due to the problem of possible spontaneous progressive seizure reduction over the course of the trial, as noted above. Perhaps the most compelling practical argument against crossover trials is the preference expressed by some regulatory bodies for other designs. Parallel designs may be the only possibility in situations where the clinical state of the patient is rapidly changing, for instance studies of status epilepticus, and the presurgical withdrawal trials considered below. Notwithstanding the above, crossover designs continue to be widely used. Patients with epilepsy show great inter-subject variability and several factors are known to affect prognosis. It is therefore difficult to obtain suitably matched groups for parallel trials and it is necessary to rely on the investigation of sufficient numbers of patients for effects of relevant inter-subject differences to be overcome by appropriate statistical analysis. Within patients, crossover trials give greater power: if all subjects responded to a trial drug, one could achieve the 5% level of significance by the sign test with only seven patients. In general it is estimated that a parallel design will require three to six times more subjects to achieve power eqivalent to that of a crossover trial. With increasing numbers of new AEDs currently undergoing clinical testing, recruitment of suitable patients at sites with research expertise in epilepsy is becoming difficult. Sufficient subjects for a parallel design may often be obtainable only by resorting to a multicentre trial, which leads in turn to other difficulties arising from differences in patient populations or in clinical practice between the different centres. In practice, the power of the crossover design may be an overriding consideration in planning drug development.
ALTERNATIVE TRIAL DESIGNS
Several variants on traditional designs are available. They are often complex and interactive and may be under-used because of per- ceived difficulties in their administration. In a response-conditional crossover design (Fig. 2) , patients are randomized to an initial treatment, either active or placebo, and remain on this if there is a specified reduction in seizure frequency with respect to baseline. This approach avoids the ethical problem of transferring patients from treatment to which they have apparently responded. If the trial drug is highly efficacious in the test population, the number of patients receiving placebo will be greatly reduced, potentially halved. Reduction of exposure to placebo is also achieved by an enriched parallel design (Fig.  3) . Here the patients commence add-on treatment with the trial drug under open-label conditions. This permits adverse effects to be closely monitored and the dose to be escalated until seizure control is achieved, or to the limits of tolerance. In patients who apparently respond, the dose is optimized and they then enter a double-blind controlled phase in which they are randomized either to placebo or to continuation of the active substance. Provided withdrawal seizures can be avoided, which will give a spurious advantage to the active drug in the randomized phase, this method offers the advantages of a parallel design but with increased power, as only subjects who apparently respond enter the controlled phase. The advantages of dose optimization under open conditions are considerable if there are problems of drug interactions or uncertainty about the therapeutic range.
MONOTHERAPY TRIALS
Increasing attention has recently been directed to ethically acceptable monotherapy designs. One approach, first adopted by Bourgeois et a111, in the development of felbamate is the performance of monotherapy trials in patients whose AEDs have been withdrawn to facilitate capture of seizures by telemetry, as part of a preoperative assessment protocol. Seizure count was lower on felbamate than placebo (P < 0.028) and only 46% of patients suffered four seizures within 28 days on felbamate, whereas 88% did so on placebo (P < 0.001).
The conduct of such trials is difficult and complex. The patients are in an unstable state and there may be only a brief interval between capturing sufficient seizures to meet the needs of preoperative assessment and the onset of serial seizures demanding immediate control. To be of demonstrable efficacy under these circumstances the test drug must act swiftly. If the half-life is long or efficacy depends on an active metabolite and several days are required to build up a therapeutic concentration, the opportunity to prove an effect may be missed. In many patients it may be impossible to achieve monotherapy if seizure frequency increases rapidly before the existing medication is fully withdrawn (as was the case in the study of Bourgeois et all1). Variants of this design have been used by the author, for an open trial of remacemide 12, and for a controlled trial of tiagabine, in which the test treatments were introduced prior to withdrawal of other medication. This last approach may avoid many of the difficulties described above, but will prolong the period of telemetry in patients who respond to the active treatment.
A less radical means of achieving monotherapy is by progressive withdrawal of comedication. This is often done under open conditions in continuation studies of patients who have responded to the test drug in controlled trials. A more active approach to this design was adopted by Faught et a113 in a study of felbamate. Test medication was introduced and escalated over 1 week. Progressive reduction of co-medication over 4 weeks was then immediately begun without awaiting a possible response. Escape criteria were specified, requiring standard medication to be resumed if seizures increased to an unacceptable level. A further unusual and possible controversial feature of this trial was the choice of control: sodium valproate in a low dose assumed to be subtherapeutic was used as a substitute for a placebo. This apparently was acceptable to the ethical review committee concerned, and indeed does not appear to involve any unacceptable risk to patients. However, as most of the patients receiving the low-dose 'active control' suffered an increase in seizures and escaped, it may be argued that the use of an inactive control would have been no less acceptable and would have given a more easily interpretable result. In the event, 40% of patients escaped on felbamate and 78% on lowdose valproate, a result significantly in favour of the former (P < 0.001).
Monotherapy trials are also feasible in newly diagnosed patients in whom there is arguably no absolute necessity for immediate effective treatment. The ethical considerations are, however, less straightforward than they might at first appear. It may be argued that patients who do not need antiepileptic treatment, particularly those who after a single seizure do not technically have epilepsy, should not be exposed to the risks, inconvenience and stigma of taking AEDs. Conversely, there is an increasing body of evidence to suggest that the long-term prognosis for terminal remission of newly diagnosed epilepsy is dependent on the speed with which treatment is started and seizures controlled. This may be taken to support an ethical case against starting treatment with a drug of uncertain efficacy. This argument does not preclude trials in newly diagnosed patients, but does suggest that they should not be undertaken until efficacy and safety are well established, i.e. in phase IV. Both of these different ethical arguments lead to the conclusion that early testing of new drugs for epilepsy is likely to remain confined to that minority of patients whose epilepsy is refractory to established medication, and that product licences for new AEDs will be correspondingly restricted.
OUTCOME
It is, perhaps belatedly, becoming increasingly realised that the needs of people with epilepsy are not met simply by control of seizures. An important consideration in marketing of AEDs is the recognition that some may offer considerable advantages over their competitors in terms of quality of life.
Simultaneous recognition of both these propositions has led to the inclusion of increasingly sophisticated quality of life measures among the outcome variables of AED trials.
Seizure-related variables relate both to occurrence and severity of attacks. Occurrence is traditionally measured as frequency, but seizure-free days or inter-seizure interval may be more sensitive to therapeutic effect if attacks occur in clusters, and are indices more relevant to the disruption of the patient's life.
Because of the very large scatter of seizure frequencies between trial subjects, simple parametric statistics based on mean seizure frequency across patients may be less powerful than such methods as the sign test or the Wilcoxon signed ranks test, which can be used for within patients comparisons in crossover trials. The proportion of patients achieving a 50% seizure reduction is widely used as a measure of 'clinically significant' change. This measure is, however, probably overrated as a means of comparing trial outcomes; the 'therapy-resistant patient' is not an inbred laboratory animal suitable for a standardized bioassay, and the results depend on the degree of intractability displayed by the patients at different sites. It is indeed striking how consistent are the differences between major trial centres when investigating different AEDs.
.Other seizure-related outcome measures worth considering include severity (seizure classification, falling and injury, loss of consciousness, confusion and automatism, incontinence, etc.) and the patient's perceived degree of control (time of occurrence, premonitory symptoms, predictability of seizures).
The development of non-seizure-related quality of life measures relevant to epilepsy is as yet in an early stage. Areas of concern include cognitive function, affect, impact on education and employment, friendship, family relations and psychosexual function, possession of a driving licence, restriction of activities, and the sense of stigmatization. Such measures are beginning to be used in AED trials and prove sensitive to the effects of treatment 14.
CONCLUSION
Whilst epileptologists can only welcome the development of drugs which are of benefit to the most seriously disadvantaged patients, there remains an urgent need for new, safe, less sedative, non-teratogenic agents to improve the quality of life for the much-larger majority of patients whose difficulties are not solved by seizure control alone. Improved drug development programmes to achieve early registration for monotherapy in non-resistant patients have yet to be devised.
